Glembatumumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Glembatumumab Usage And Synthesis

Uses

Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity[1].

in vivo

References

[1] Naumovski L, et al. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010 Apr;12(2):248-57. PMID:20373269
[2] E Anders Kolb, et al. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Oct;61(10):1816-21. DOI:10.1002/pbc.25099
[3] Xiaozhong Qian, et al. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol Oncol. 2008 Jun;2(1):81-93. DOI:10.1016/j.molonc.2008.02.002

Glembatumumab(1020264-78-1)Related Product Information

• Blinatumomab
• Simtuzumab
• Andecaliximab
• citatuzumab
• Sutimlimab
• Leronlimab
• Girentuximab
• Plozalizumab
• Durvalumab
• Foravirumab